Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab vs Bevacizumab for Type 1 ROP
NCT05033106Phase 3Unknown
- Sponsor
- Zagazig University
- Start
- Sep 2020
- Primary completion
- Sep 2022
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label trial of ranibizumab and bevacizumab in retinopathy of prematurity (ROP) (2 arms), sponsored by Zagazig University. Primary endpoint: Regression achieved either by single injection or multiple injections or additional laser therapy. Status: unknown.
02
Drugs
ranibizumabbevacizumab
03
Conditions
retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on NCT05033106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05033106.